CEL-SCI Corporation (CVM) and VIVUS Inc. (NASDAQ:VVUS) Contrasting side by side

CEL-SCI Corporation (NYSEAMERICAN:CVM) and VIVUS Inc. (NASDAQ:VVUS) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CEL-SCI Corporation N/A 176.74 31.85M -1.72 0.00
VIVUS Inc. 56.89M 0.97 42.52M -3.98 0.00

Table 1 demonstrates CEL-SCI Corporation and VIVUS Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
CEL-SCI Corporation 0.00% 704.1% -97.8%
VIVUS Inc. -74.74% 182.8% -15.1%

Risk and Volatility

CEL-SCI Corporation’s current beta is 0.84 and it happens to be 16.00% less volatile than S&P 500. Competitively, VIVUS Inc.’s 29.00% volatility makes it less volatile than S&P 500, because of the 0.71 beta.

Liquidity

0.4 and 0.3 are the respective Current Ratio and a Quick Ratio of CEL-SCI Corporation. Its rival VIVUS Inc.’s Current and Quick Ratios are 4.4 and 3.8 respectively. VIVUS Inc. has a better chance of clearing its pay short and long-term debts than CEL-SCI Corporation.

Institutional and Insider Ownership

CEL-SCI Corporation and VIVUS Inc. has shares owned by institutional investors as follows: 6.6% and 18.3%. About 5.6% of CEL-SCI Corporation’s share are owned by insiders. Insiders Competitively, owned 0.7% of VIVUS Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CEL-SCI Corporation -3.66% -0.32% -18.56% 13.67% 79.55% 67.21%
VIVUS Inc. 3.53% -25.82% -37.79% -66.7% -52.05% -41.7%

For the past year CEL-SCI Corporation had bullish trend while VIVUS Inc. had bearish trend.

Summary

CEL-SCI Corporation beats VIVUS Inc. on 6 of the 9 factors.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companyÂ’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.